Renewal with extension
Facts
On 2026-03-15 Acme and the Company executed a renewal agreement covering the period 2026-03-15 through 2027-03-14. The renewal increases the monthly commit to $110,000 and consolidates Premium Support and corrected overage into a single new agreement. The remaining 17 days of the original-term March (2026-03-15 through 2026-03-31) are superseded by the renewal terms.
Treatment determination
Per the SSP analysis dated 2026-03-10, the renewal price does not reflect standalone selling price of the remaining services; the remaining services are not distinct from those provided under the renewal. The criteria of 25-12 are not met. Under 25-13(c),1 the modification is accounted for as a termination of the existing contract and the creation of a new contract; remaining unrecognized consideration from the original contract is combined with the new consideration and recognized prospectively over the new contract term.
Revenue schedule impact
Periods 2026-01 and 2026-02 are unchanged from the post-amendment-3 baseline. The 17-day stub of original-term March ($52,097 commit at the $95,000 monthly-equivalent rate) is terminated. New contract recognition begins 2026-03-15 at $110,000 commit + $7,500 estimated overage + $3,000 Premium Support per period across the 12-month renewal term, ending 2027-03-14.
Materiality assessment
Δ consolidated TCV is approximately $1.39 million, representing 440% of the prior $315,758 baseline; well above the 5% materiality threshold. Disclosure is required in the 2026-Q1 contract activity memo and on the auditor PBC list. The SSP study (2026-03-10) and term-combination test working paper are required attachments. Renewal commission accrual schedule is amended in parallel under the related ASC 340-40 work; cross-reference workpaper RR-04 in this PBC bundle.
- [1]ASC 606-10-25-13(c)